Day: March 12, 2024

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today issued the following letter to shareholders. To my fellow shareholders: Having recently commenced trading on the Nasdaq stock exchange under the ticker “PBM,” following the completion of our business combination with Newcourt Acquisition Corp., I am happy to write to update you on our recent progress and upcoming milestones. Our merger with Newcourt and subsequent listing on Nasdaq confers numerous benefits to our company. These include expanded access to capital to fund our development programs and the opportunity to share the Psyence story more broadly and garner support from more sophisticated long-term institutional...

CHICAGO, March 12, 2024 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the fourth quarter and year ended December 31, 2023. John Mazarakis, Executive Chairman of Chicago Atlantic noted, “The improvement in the regulatory landscape has fed new investment opportunities for us while significantly improving the equity value of many of our borrowers. In addition, the wall of debt maturities we have anticipated among the larger cannabis operators is beginning to occur, with early indications this opportunity could be as meaningful over the next 12 to 18 months as we have previously predicted. We intend to utilize our direct lending expertise and leading platform in the cannabis space...

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product. Bucillamine The Company is advancing the research and development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID and medical countermeasures, such as nerve agent exposure. Chemical Warfare – Nerve Agent Exposure Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The...

New Data Shows Clinicians Save Up to 1 Hour or More per Day Using Augmedix Go SAN FRANCISCO, March 12, 2024 (GLOBE NEWSWIRE) — Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced new positive data and product enhancements for Augmedix Go, its ambient AI medical documentation product. Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients. New data from survey responses from more than a dozen enterprise and independent healthcare organizations found that clinicians in ambulatory care settings save up to one hour or more per clinic day by using Augmedix Go. Additionally, 94% of clinicians surveyed reported...

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company, through its 100% owned subsidiary Bralorne Gold Mines Ltd. (“Bralorne”), has signed a definitive Ore Purchase Agreement (the “Agreement”) with New Gold Inc. (“New Gold”). As part of the Agreement New Gold will purchase up to 350,000 tonnes of material mined at Bralorne and process it at their mill located at its New Afton mine. The Agreement can be extended by mutual agreement by New Gold and Talisker. Terry Harbort, Talisker’s President and CEO commented, “Talisker is very pleased to have signed this important ore purchase agreement with New Gold. Having completed the portal and decline construction and our resource conversion drilling, this Agreement clears the pathway...

SUNNYVALE, Calif., March 12, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS previously published a New Technology APC (Ambulatory Payment Classifications) code that covers the CardiAMP Cell Therapy investigational study procedure, including the BioCardia investigational products utilized to perform...

Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY programs Conference call and webcast set for 8:00 a.m. ET today NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023. “We believe our late-stage programs evaluating BXCL501 for acute agitation associated with Alzheimer’s dementia, bipolar disorders, and schizophrenia represent groundbreaking...

LONDON, March 12, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP inspection by the MHRA in February 2024, Autolus’ Nucleus manufacturing facility in Stevenage has obtained a Manufacturer’s Importation Authorisation (MIA) together with the accompanying GMP certificate. This authorisation enables Autolus to manufacture for global commercial and clinical product supply from the Nucleus effective as of March 18, 2024. Following a full site inspection in February 2024, Autolus’s Nucleus site has recently received the formal certification from the MHRA. The MHRA issued two new licenses to cover both clinical and commercial manufacture from the site and found no major or...

Declares Regular Quarterly Dividend GARDEN CITY, N.Y., March 12, 2024 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, today reported its financial results for the quarter and full year ended December 31, 2023. Rob Kay, Lifetime’s Chief Executive Officer, commented, “We closed out 2023 with another strong quarter, delivering results that met or exceeded both internal and analyst expectations for net sales, income from operations and adjusted EBITDA. We are pleased with this outperformance, paced by sales growth we are seeing across the business, most notably in our core U.S. Kitchenware category, where we saw substantial gains in the fourth quarter. As we hone our online strategy, we are also gaining market...

Acquisition follows entry into an agreement granting CoinShares an exclusive option to acquire Valkyrie Funds LLC (“Valkyrie”) and the Sponsor rights to BRRR, Valkyrie’s physically-backed Bitcoin ETF Valkyrie’s regulatory licences are complementary to CoinShares’ existing U.S. permissions and contribute to establishing solid foundations for CoinShares to continue executing its U.S. asset management expansion plan. It provides CoinShares with a promising platform to expand its digital assets expertise into the United States and contributes approximately $530 million of new assets under management from $BTF, $WGMI, $BRRR, and $BTFX. CoinShares plans to rebrand Valkyrie as the Company’s U.S. asset management platform that will concentrate on creating innovative products that stand out in the market. Valkyrie’s product line will eventually...